• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Accuray Appoints Jean-Philippe Pignol, M.D., Ph.D. as Chief Medical & Technology Officer

    4/26/21 7:30:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care
    Get the next $ARAY alert in real time by email

    SUNNYVALE, Calif., April 26, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Jean-Philippe Pignol, M.D., Ph.D. as its chief medical & technology officer, effective as of April 15, 2021. In this new role, Dr. Pignol will lead the company's scientific and clinical research activities, develop strategic collaborations with global key opinion leaders, evaluate new technologies and serve as the executive representative with important industry partners including medical societies, regulatory and legislative agencies that influence healthcare policy and reimbursement.

    Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)

    "We're thrilled to welcome Dr. Pignol, whose rich and unique experience base within the global radiation therapy community will help the Accuray team to achieve its vision of 'expanding the curative power of radiation therapy.' He joins the company at an important time in its growth and is a key addition to our executive leadership team," said Joshua H. Levine, president and chief executive officer.

    "Dr. Pignol is a visionary with an incredible background of work with industry partners and track record of publications in the radiation therapy space," said Suzanne Winter, chief commercial officer and senior vice president, R&D at Accuray. "His clinical expertise will inform innovation, technology and new business development opportunities for the company designed to drive the personalization of radiation therapy treatments and positively change the lives of those with cancer or neurological diseases."

    Dr. Pignol brings more than 26 years of experience in academia and clinical practice. For the past three years, he has served as professor and department head of the department of radiation oncology at Dalhousie University in Halifax, Canada. Previously, Dr. Pignol spent four years as professor and chair of the department of radiation oncology at Erasmus MC in Rotterdam, the Netherlands. As a board-certified radiation oncologist, he also has vast experience treating patients and has practiced throughout North America and Europe, including at the University of Toronto, Sunnybrook Cancer Center in Toronto, Canada and cancer institutes across France.

    Additionally, Dr. Pignol has extensive research experience having led and participated in clinical trials designed to evaluate a wide-range of topics including the benefits of technical innovation in reducing treatment side effects for breast cancer patients, and new techniques and applications for the delivery of radiation therapy. He has authored over 125 peer-reviewed publications and was the first radiation oncologist to demonstrate the clinical benefits of intensity-modulated radiation therapy (IMRT), with a paper published in the Journal of Clinical Oncology.

    "All my career has been spent in clinical care and research, developing new modalities of radiation treatments, to enable me to learn first-hand the benefits that radiation therapy can provide to patients. With the right technology, this treatment modality helps enable patients to not just live longer, but to live better and to thrive," said Jean-Philippe Pignol, M.D., Ph.D., chief medical & technology officer at Accuray. "I believe the field of Radiation Oncology is at a turning point where adaptive radiotherapy and ultra-hypofractionated regimens need optimal and dedicated solutions, where the target motion is fully controlled in real time on machines that can treat every tumor site. I have long been very impressed by Accuray and the very innovative radiation therapy delivery systems its global team has brought to market."

    About Accuray

    Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.

    Safe Harbor Statement

    Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the ability of the company's executives to help the company achieve its vision and inform innovation, technology and new business development opportunities for the company as well as the company's leadership position in radiation oncology innovation and technologies. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 1, 2021, and as updated periodically with the company's other filings with the SEC.

    Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

    Media Contact

    Beth Kaplan         

    Accuray   

    +1 (408) 789-4426          

    [email protected]

    Investor Contact

    Joe Diaz

    Investor Relations - Accuray

    +1 (602) 717-7804

    [email protected]

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/accuray-appoints-jean-philippe-pignol-md-phd-as-chief-medical--technology-officer-301276397.html

    SOURCE Accuray Incorporated

    Get the next $ARAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARAY

    DatePrice TargetRatingAnalyst
    2/13/2024$9.00Buy
    ROTH MKM
    6/23/2022$7.50Buy
    B. Riley Securities
    12/22/2021$7.50Buy
    Loop Capital
    More analyst ratings

    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Whitters Joseph E bought $62,335 worth of shares (50,000 units at $1.25), increasing direct ownership by 9% to 611,053 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      6/16/25 4:10:10 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Whitters Joseph E bought $156,045 worth of shares (100,000 units at $1.56), increasing direct ownership by 22% to 561,053 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      5/30/24 4:10:11 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Whitters Joseph E bought $62,335 worth of shares (50,000 units at $1.25), increasing direct ownership by 9% to 611,053 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      6/16/25 4:10:10 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Mayer Steven F

      3 - ACCURAY INC (0001138723) (Issuer)

      6/16/25 4:10:07 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SVP, Chief Commercial Officer Chalke Sandeep covered exercise/tax liability with 35,123 shares, decreasing direct ownership by 7% to 471,469 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      6/3/25 4:10:19 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by Accuray Incorporated

      SCHEDULE 13D - ACCURAY INC (0001138723) (Subject)

      6/17/25 1:25:59 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - ACCURAY INC (0001138723) (Filer)

      6/6/25 7:36:36 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Accuray Incorporated

      SD - ACCURAY INC (0001138723) (Filer)

      5/30/25 4:01:08 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Accuray with a new price target

      ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00

      2/13/24 6:29:42 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities initiated coverage on Accuray with a new price target

      B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

      6/23/22 7:25:39 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Loop Capital initiated coverage on Accuray with a new price target

      Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

      12/22/21 4:56:14 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities

      MADISON, Wis., June 6, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced that, after an extensive review over the last several months, including the evaluation of numerous potential financing partners, it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2026 (the "Notes") to exchange an aggregate of $82.0 million principal amount of Notes for an aggregate of 8,881,579 shares of the Accuray's common stock (the "Shares"). As part of the exchange consideration, Accuray will pay exchanging holders an aggregate of approximately $68.6 million in cash. The Exchange is expected to close on or about June 11, 202

      6/6/25 7:30:00 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray to Participate in the Jefferies Global Healthcare Conference 2025

      MADISON, Wis., May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025. The management team is scheduled to participate in a fireside chat on Wednesday, June 4th, 2025, at 5:30pm EDT/2:30pm PDT. A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available for 90 days. About AccurayAccuray is committed to expanding the powerful potential o

      5/29/25 7:30:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025

      More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis., May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey. The studies, shared at the annual congress held in Vienna, Austria, indicate the system's accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body r

      5/7/25 7:35:00 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care